Pfizer Cardura XL “Approvable”
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer will "respond promptly" to FDA's "approvable" letter for Cardura XL, marketing partner Andrx says.
You may also be interested in...
Pfizer’s Cardura XL Clears FDA For Benign Prostatic Hyperplasia
The extended-release formulation of doxazosin has a narrower indication than the immediate-release formulation but allows for less frequent dose titration. Both formulations are once-daily.
Pfizer’s Cardura XL Clears FDA For Benign Prostatic Hyperplasia
The extended-release formulation of doxazosin has a narrower indication than the immediate-release formulation but allows for less frequent dose titration. Both formulations are once-daily.
Andrx Drops Cardura XL Distribution Deal In Move Away From Brand Business
Company moves to terminate a supply and distribution deal with Pfizer because the BPH agent failed to receive FDA approval by Dec. 31, 2004. Andrx is divesting its brand business to focus on its "core competencies" of controlled-release formulation development and distribution.